Nicardipine Aguettant (Nicardipine Hydrochloride)

Nicardipine Hydrochloride selectively blocks L‑type calcium channels on arterial smooth muscle, preventing calcium entry. This causes arterial vasodilation, reduces peripheral vascular resistance, lowers blood pressure, and improves coronary blood flow, thereby relieving cardiac workload.

The dosage of Nicardipine Aguettant is determined by the prescribing clinician based on the patient’s clinical status, blood‑pressure targets, and response to therapy. The prescriber sets the infusion rate and duration according to established guidelines.

Safety data for Nicardipine in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Nicardipine is a dihydropyridine with a rapid onset and short duration, making it suitable for intravenous use in acute settings. Compared with oral agents like amlodipine, it allows precise titration and immediate blood‑pressure control, but requires careful monitoring for hypotension.

Nicardipine Aguettant should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the solution from light and moisture, and avoid freezing. Inspect the vial for particulate matter before use.

The product is supplied as an intravenous solution for infusion. It is administered by controlled IV infusion, typically using a calibrated pump, with the rate adjusted by the clinician based on blood‑pressure response and patient tolerance.

Serious risks include severe hypotension, myocardial infarction, life‑threatening arrhythmias, and allergic reactions such as anaphylaxis. Patients should be monitored continuously for hemodynamic changes and signs of cardiac ischemia during infusion.

Nicardipine is contraindicated in patients with known hypersensitivity to nicardipine or any component of the formulation, and it should be used with extreme caution in individuals with severe aortic stenosis, uncontrolled heart failure, or profound hypotension.